Literature DB >> 23327522

Toward a universal influenza virus vaccine: prospects and challenges.

Natalie Pica1, Peter Palese.   

Abstract

Current influenza virus vaccines are annually reformulated to elicit protection by generating an immune response toward the virus strains that are predicted to circulate in the upcoming influenza season. These vaccines provide limited protection in cases of antigenic mismatch, when the vaccine and the circulating viral strains differ. The emergence of unexpected pandemic viruses presents an additional challenge to vaccine production. To increase influenza virus preparedness, much work has been dedicated to the development of a universal vaccine. Focusing on regions of viral proteins that are highly conserved across virus subtypes, vaccine strategies involving the matrix 2 protein, stalk domain of the hemagglutinin, and multivalent approaches have provided broad-based protection in animal models and show much promise. This review summarizes the most encouraging advances in the field with a focus on novel vaccine designs that have yielded promising preclinical and clinical data.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23327522     DOI: 10.1146/annurev-med-120611-145115

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  130 in total

1.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Authors:  Helder I Nakaya; Thomas Hagan; Sai S Duraisingham; Eva K Lee; Marcin Kwissa; Nadine Rouphael; Daniela Frasca; Merril Gersten; Aneesh K Mehta; Renaud Gaujoux; Gui-Mei Li; Shakti Gupta; Rafi Ahmed; Mark J Mulligan; Shai Shen-Orr; Bonnie B Blomberg; Shankar Subramaniam; Bali Pulendran
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

Review 3.  Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.

Authors:  Dong Hyun Kim; Han Sol Lee; Tae-Wan Kwon; Young-Min Han; Nae-Won Kang; Mee Yeon Lee; Dae-Duk Kim; Myeong Gyu Kim; Jae-Young Lee
Journal:  Arch Pharm Res       Date:  2020-01-27       Impact factor: 4.946

4.  The anti-influenza virus effect of Phellinus igniarius extract.

Authors:  Sangmoo Lee; Jin Il Kim; Jun Heo; Ilseob Lee; Sehee Park; Min-Woong Hwang; Joon-Yong Bae; Mee Sook Park; Hyoung Jin Park; Man-Seong Park
Journal:  J Microbiol       Date:  2013-10-31       Impact factor: 3.422

5.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

Authors:  Chadi M Saad-Roy; Adrian B McDermott; Bryan T Grenfell
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

6.  Exploring the potential public health benefits of universal influenza vaccine.

Authors:  Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown
Journal:  Hum Vaccin Immunother       Date:  2019-06-18       Impact factor: 3.452

7.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

8.  Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine.

Authors:  Aitor Nogales; Laura Rodriguez; Caroline Chauché; Kai Huang; Emma C Reilly; David J Topham; Pablo R Murcia; Colin R Parrish; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

10.  Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development.

Authors:  Aitor Nogales; Steven F Baker; Emilio Ortiz-Riaño; Stephen Dewhurst; David J Topham; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.